FDA, again [R for BE/BA]

posted by Helmut Homepage – Vienna, Austria, 2020-01-09 16:04 (567 d 19:14 ago) – Posting: # 21070
Views: 2,951

[image] Dear all,

we know that the FDA uses [image] internally, e.g., in all simulations which lead to its reference-scaling method for NTIDs.

THX to ElMaestro discovering another example. Though I attended the 4th GBHI workshop last month in Bethesda, it is hidden in the backup slides.* Quote:

Q1. What is a sample size to achieve 80% power to pass bioequivalence, assuming CV as 100%, T/R true ratio as 5%?
Q2. With a fixed sample size (n=1,000), what are maximum differences in FEV1 metrics which pass BE with 80% power?

To address questions 1–2;

Of note, Robert Lionberger (Director Office of Research and Standards, Office of Generic Drugs) told me that he visits the forum regularly. :thumb up:

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,592 posts in 4,514 threads, 1,532 registered users;
online 8 (0 registered, 8 guests [including 5 identified bots]).
Forum time: Friday 12:19 CEST (Europe/Vienna)

It is a capital mistake to theorise before one has data.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz